deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02652624

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women

Sponsor: Gilead Sciences

Conditions HIV-1 Infection
Interventions ATV B/F/TAF E/C/F/TAF E/C/F/TDF FTC/TDF RTV
Updated 15 times since 2017 Last updated: Feb 18, 2020 Started: Feb 19, 2016 Primary completion: Oct 9, 2017 Completion: Nov 26, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV-1 Infection and is currently completed. Gilead Sciences leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Dec 2019 · 10 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 10 earlier versions

  1. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Dec 2019 — Apr 2020 [monthly]

    Completed PHASE3

  4. Feb 2019 — Dec 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Bangkok, Thailand , Barnaul, Russia , Bellaire, United States , Charlotte, United States , Chiang Mai, Thailand , Dallas, United States , Decatur, United States , Durham, United States , Fort Lauderdale, United States and 36 more locations